Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

Biochemistry - 16 Jun 2009

Timofeevski Sergei L, McTigue Michele A, Ryan Kevin, Cui Jean, Zou Helen Y, Zhu Jeff X, Chau Fannie, Alton Gordon, Karlicek Shannon, Christensen James G, Murray Brion W

Abstract excerpt

The c-Met receptor tyrosine kinase (RTK) is a key regulator in cancer, in part, through oncogenic mutations. Eight clinically relevant mutants were characterized by biochemical, biophysical, and cellular methods. The c-Met catalytic domain was highly active in the unphosphorylated state (k(cat) =...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Catalysis
Share to Kinetics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphorylation

Share to Protein Conformation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Share to Pyrazines

Source

Identifiers

PMID: 19459657
DOI: 10.1021/bi900438w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19459657-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.PMID 19459657Read ↗

Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.Semantic proximity Read ↗

Tyrosine kinase mutations in human cancer.Semantic proximity Read ↗

Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.Semantic proximity Read ↗

Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.Semantic proximity Read ↗

Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical CandidatesSemantic proximity Read ↗

MET in human cancer: germline and somatic mutationsSemantic proximity Read ↗

Cell lines expressing recombinant transmembrane domain-activated receptor kinases as tools for drug discovery.Semantic proximity Read ↗

Regulation of the wild-type and Y1235D mutant Met kinase activation.Semantic proximity Read ↗

Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation.Semantic proximity Read ↗

MET receptor sequence variants R970C and T992I lack transforming capacity.Semantic proximity Read ↗

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.Semantic proximity Read ↗

Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.